Maravai LifeSciences Holdings (MEX:MRVI) Piotroski F-Score: 3 (As of Jun. 27, 2026) — 25% Below Median


MEX:MRVI Maravai LifeSciences Holdings Inc MEX:MRVI
62 GF Score
Price MXN85.00
GF Value MXN53.06
! 8 Warning Signs
View Full Analysis

What is Maravai LifeSciences Holdings Piotroski F-Score?

Maravai LifeSciences Holdings MEX:MRVI 62 Piotroski F-Score is 3 as of Jun. 27, 2026, which is 25% below its 10-year median of 4.00. GuruFocus rates MEX:MRVI with a GF Score™ of 62/100 and a GF Value™ of MXN53.06. The stock has 8 warning signs investors should review. Among 1,342 Biotechnology companies, Maravai LifeSciences Holdings ranks better than 54.99% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Maravai LifeSciences Holdings has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Maravai LifeSciences Holdings's Piotroski F-Score or its related term are showing as below:

MEX:MRVI' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 8
Current: 3

During the past 8 years, the highest Piotroski F-Score of Maravai LifeSciences Holdings was 8. The lowest was 2. And the median was 4.

Maravai LifeSciences Holdings  (MEX:MRVI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Maravai LifeSciences Holdings Piotroski F-Score Related Terms


Maravai LifeSciences Holdings Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Maravai LifeSciences Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maravai LifeSciences Holdings Piotroski F-Score Chart

Maravai LifeSciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 8.00 5.00 4.00 4.00 2.00

Maravai LifeSciences Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 2.00 3.00 2.00 3.00

MEX:MRVI vs ANRO, BBOT, REPL: Piotroski F-Score Comparison

For the Biotechnology subindustry, Maravai LifeSciences Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maravai LifeSciences Holdings Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Maravai LifeSciences Holdings's Piotroski F-Score falls into.


MEX:MRVI
62GF Score
Maravai LifeSciences Holdings Inc MEX:MRVI
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -745.467 + -468.804 + -642.461 + -67.316 = MXN-1,924 Mil.
Cash Flow from Operations was -193.282 + -277.915 + -409.954 + 156.253 = MXN-725 Mil.
Revenue was 892.448 + 763.669 + 897.872 + 1187.219 = MXN3,741 Mil.
Gross Profit was 146.265 + 103.736 + 231.229 + 607.72 = MXN1,089 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(19634.778 + 16889.152 + 15577.73 + 13874.778 + 12861.228) / 5 = MXN15767.5332 Mil.
Total Assets at the begining of this year (Mar25) was MXN19,635 Mil.
Long-Term Debt & Capital Lease Obligation was MXN4,787 Mil.
Total Current Assets was MXN4,539 Mil.
Total Current Liabilities was MXN769 Mil.
Net Income was -179.335 + -1911.416 + -540.267 + -612.621 = MXN-3,244 Mil.

Revenue was 1271.837 + 1359.123 + 1179.557 + 958.467 = MXN4,769 Mil.
Gross Profit was 565.01 + 634.697 + 404.392 + 158.04 = MXN1,762 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(23975.63 + 26520.328 + 25168.437 + 21027.634 + 19634.778) / 5 = MXN23265.3614 Mil.
Total Assets at the begining of last year (Mar24) was MXN23,976 Mil.
Long-Term Debt & Capital Lease Obligation was MXN7,454 Mil.
Total Current Assets was MXN7,698 Mil.
Total Current Liabilities was MXN1,292 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Maravai LifeSciences Holdings's current Net Income (TTM) was -1,924. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Maravai LifeSciences Holdings's current Cash Flow from Operations (TTM) was -725. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-1924.048/19634.778
=-0.09799184

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-3243.639/23975.63
=-0.135289

Maravai LifeSciences Holdings's return on assets of this year was -0.09799184. Maravai LifeSciences Holdings's return on assets of last year was -0.135289. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Maravai LifeSciences Holdings's current Net Income (TTM) was -1,924. Maravai LifeSciences Holdings's current Cash Flow from Operations (TTM) was -725. ==> -725 > -1,924 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=4786.6/15767.5332
=0.30357317

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=7453.863/23265.3614
=0.32038458

Maravai LifeSciences Holdings's gearing of this year was 0.30357317. Maravai LifeSciences Holdings's gearing of last year was 0.32038458. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=4539.48/768.59
=5.9062439

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=7698.052/1292.099
=5.95778806

Maravai LifeSciences Holdings's current ratio of this year was 5.9062439. Maravai LifeSciences Holdings's current ratio of last year was 5.95778806. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Maravai LifeSciences Holdings's number of shares in issue this year was 146.426. Maravai LifeSciences Holdings's number of shares in issue last year was 143.425. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1088.95/3741.208
=0.29106909

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1762.139/4768.984
=0.36949988

Maravai LifeSciences Holdings's gross margin of this year was 0.29106909. Maravai LifeSciences Holdings's gross margin of last year was 0.36949988. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=3741.208/19634.778
=0.19053987

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=4768.984/23975.63
=0.19890964

Maravai LifeSciences Holdings's asset turnover of this year was 0.19053987. Maravai LifeSciences Holdings's asset turnover of last year was 0.19890964. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Maravai LifeSciences Holdings has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Maravai LifeSciences Holdings (MEX:MRVI) has a Piotroski F-Score of 3 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Maravai LifeSciences Holdings and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Maravai LifeSciences Holdings' Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Maravai LifeSciences Holdings ranks #604 out of 1342 companies in the Biotechnology industry, placing it in the top 45%.
Is Maravai LifeSciences Holdings' Piotroski F-Score too high?
Maravai LifeSciences Holdings' current Piotroski F-Score of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Biotechnology industry median Piotroski F-Score is 3.00. Maravai LifeSciences Holdings' value of 3 is 0% at this industry median. Based on the distribution chart, Maravai LifeSciences Holdings ranks #604 out of 1342 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Maravai LifeSciences Holdings has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' Piotroski F-Score compare to ANRO and BBOT?
According to the Biotechnology industry distribution chart, Maravai LifeSciences Holdings ranks #604 out of 1342 companies for Piotroski F-Score. This puts Maravai LifeSciences Holdings in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Maravai LifeSciences Holdings' value of 3 is 0% at this benchmark. Historically, Maravai LifeSciences Holdings' own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Maravai LifeSciences Holdings has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maravai LifeSciences Holdings's current Piotroski F-Score of 3 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Maravai LifeSciences Holdings and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maravai LifeSciences Holdings's current Piotroski F-Score is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Maravai LifeSciences Holdings (MEX:MRVI) has a current Piotroski F-Score of 3. The stock's GF Value™ is MXN53.06, compared to a current price of MXN85.00 — trading 60.2% above its estimated fair value. The current Piotroski F-Score is 3, which is 25% below median its 10-year median of 4.00 and 0% at the Biotechnology industry median of 3.00. Maravai LifeSciences Holdings' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MEX:MRVI), the current Piotroski F-Score is 3 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maravai LifeSciences Holdings (MEX:MRVI) Overvalued in 2026?

Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued. The current stock price of MXN85.00 is trading 60.2% above its estimated GF Value™ of MXN53.06.

Key valuation signals for MEX:MRVI:

  • Piotroski F-Score: 3 (25% below median its 10-year median of 4.00)
  • GF Value™: MXN53.06 vs. price of MXN85.00 (60.2% above fair value)
  • GF Score™: 62/100 with 8 warning signs
  • Industry Position: 0% at the Biotechnology median (#604 of 1342)

No single metric tells the full story. See the MEX:MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Maravai LifeSciences Holdings Business Description

Other Exchanges MRVI:USAMAR:Germany
Address 10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
62GF Score

Get the complete analysis for MEX:MRVI

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN85.00
Price
MXN53.06
GF Value